Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer.

Lykkesfeldt AE, Iversen BR, Jensen MB, Ejlertsen B, Giobbie-Hurder A, Reiter BE, Kirkegaard T, Rasmussen BB.

Acta Oncol. 2018 Jan;57(1):67-73. doi: 10.1080/0284186X.2017.1404126. Epub 2017 Dec 4.

PMID:
29202611
2.

Assessment of perioperative stress in colorectal cancer by use of in vitro cell models: a systematic review.

Kirkegaard T, Gögenur M, Gögenur I.

PeerJ. 2017 Nov 17;5:e4033. doi: 10.7717/peerj.4033. eCollection 2017.

3.

Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D3.

Lundqvist J, Kirkegaard T, Laenkholm AV, Duun-Henriksen AK, Bak M, Feldman D, Lykkesfeldt AE.

J Steroid Biochem Mol Biol. 2018 Mar;177:171-178. doi: 10.1016/j.jsbmb.2017.06.003. Epub 2017 Jun 10.

PMID:
28610873
4.

A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis.

L H Weischenfeldt K, Kirkegaard T, Rasmussen BB, Giobbie-Hurder A, Jensen MB, Ejlertsen B, Lykkesfeldt AE.

Acta Oncol. 2017 Sep;56(9):1161-1167. doi: 10.1080/0284186X.2017.1324211. Epub 2017 May 10.

PMID:
28488912
5.

Differences in clinical presentation between bipolar I and II disorders in the early stages of bipolar disorder: A naturalistic study.

Vinberg M, Mikkelsen RL, Kirkegaard T, Christensen EM, Kessing LV.

J Affect Disord. 2017 Jan 15;208:521-527. doi: 10.1016/j.jad.2016.10.031. Epub 2016 Oct 25.

PMID:
27816324
6.

Expression of transmembrane protein 26 (TMEM26) in breast cancer and its association with drug response.

Nass N, Dittmer A, Hellwig V, Lange T, Beyer JM, Leyh B, Ignatov A, Weiβenborn C, Kirkegaard T, Lykkesfeldt AE, Kalinski T, Dittmer J.

Oncotarget. 2016 Jun 21;7(25):38408-38426. doi: 10.18632/oncotarget.9493.

7.

Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses.

Kirkegaard T, Gray J, Priestman DA, Wallom KL, Atkins J, Olsen OD, Klein A, Drndarski S, Petersen NH, Ingemann L, Smith DA, Morris L, Bornæs C, Jørgensen SH, Williams I, Hinsby A, Arenz C, Begley D, Jäättelä M, Platt FM.

Sci Transl Med. 2016 Sep 7;8(355):355ra118. doi: 10.1126/scitranslmed.aad9823.

PMID:
27605553
8.

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.

Alves CL, Elias D, Lyng M, Bak M, Kirkegaard T, Lykkesfeldt AE, Ditzel HJ.

Clin Cancer Res. 2016 Nov 15;22(22):5514-5526. doi: 10.1158/1078-0432.CCR-15-1984. Epub 2016 Jun 1.

9.

Accuracy of abdominal auscultation for bowel obstruction.

Breum BM, Rud B, Kirkegaard T, Nordentoft T.

World J Gastroenterol. 2015 Sep 14;21(34):10018-24. doi: 10.3748/wjg.v21.i34.10018.

10.

Regional brain volumes, diffusivity, and metabolite changes after electroconvulsive therapy for severe depression.

Jorgensen A, Magnusson P, Hanson LG, Kirkegaard T, Benveniste H, Lee H, Svarer C, Mikkelsen JD, Fink-Jensen A, Knudsen GM, Paulson OB, Bolwig TG, Jorgensen MB.

Acta Psychiatr Scand. 2016 Feb;133(2):154-164. doi: 10.1111/acps.12462. Epub 2015 Jul 3.

PMID:
26138003
11.

Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.

Larsen SL, Yde CW, Laenkholm AV, Rasmussen BB, Duun-Henriksen AK, Bak M, Lykkesfeldt AE, Kirkegaard T.

BMC Cancer. 2015 Apr 8;15:239. doi: 10.1186/s12885-015-1210-4.

12.

SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.

Larsen SL, Laenkholm AV, Duun-Henriksen AK, Bak M, Lykkesfeldt AE, Kirkegaard T.

PLoS One. 2015 Feb 23;10(2):e0118346. doi: 10.1371/journal.pone.0118346. eCollection 2015.

13.

A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.

Thrane S, Pedersen AM, Thomsen MB, Kirkegaard T, Rasmussen BB, Duun-Henriksen AK, Lænkholm AV, Bak M, Lykkesfeldt AE, Yde CW.

Oncogene. 2015 Aug 6;34(32):4199-210. doi: 10.1038/onc.2014.351. Epub 2014 Nov 3.

PMID:
25362855
14.

Lysosomal storage diseases and the heat shock response: convergences and therapeutic opportunities.

Ingemann L, Kirkegaard T.

J Lipid Res. 2014 Nov;55(11):2198-210. doi: 10.1194/jlr.R048090. Epub 2014 May 16. Review.

15.

The broad-spectrum metalloproteinase inhibitor BB-94 inhibits growth, HER3 and Erk activation in fulvestrant-resistant breast cancer cell lines.

Kirkegaard T, Yde CW, Kveiborg M, Lykkesfeldt AE.

Int J Oncol. 2014 Jul;45(1):393-400. doi: 10.3892/ijo.2014.2434. Epub 2014 May 9.

PMID:
24819550
16.

T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.

Kirkegaard T, Hansen SK, Larsen SL, Reiter BE, Sørensen BS, Lykkesfeldt AE.

Cancer Lett. 2014 Mar 1;344(1):90-100. doi: 10.1016/j.canlet.2013.10.014.

PMID:
24513268
17.

Human heat shock protein 70 (Hsp70) as a peripheral membrane protein.

Mahalka AK, Kirkegaard T, Jukola LT, Jäättelä M, Kinnunen PK.

Biochim Biophys Acta. 2014 May;1838(5):1344-61. doi: 10.1016/j.bbamem.2014.01.022. Epub 2014 Jan 28.

18.

Effects of a screening and treatment protocol with haloperidol on post-cardiotomy delirium: a prospective cohort study.

Schrøder Pedersen S, Kirkegaard T, Balslev Jørgensen M, Lind Jørgensen V.

Interact Cardiovasc Thorac Surg. 2014 Apr;18(4):438-45. doi: 10.1093/icvts/ivt501. Epub 2013 Dec 18.

19.

Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase.

Petersen NH, Olsen OD, Groth-Pedersen L, Ellegaard AM, Bilgin M, Redmer S, Ostenfeld MS, Ulanet D, Dovmark TH, Lønborg A, Vindeløv SD, Hanahan D, Arenz C, Ejsing CS, Kirkegaard T, Rohde M, Nylandsted J, Jäättelä M.

Cancer Cell. 2013 Sep 9;24(3):379-93. doi: 10.1016/j.ccr.2013.08.003.

20.

Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize lysosomes, and inhibit multidrug resistance.

Ellegaard AM, Groth-Pedersen L, Oorschot V, Klumperman J, Kirkegaard T, Nylandsted J, Jäättelä M.

Mol Cancer Ther. 2013 Oct;12(10):2018-30. doi: 10.1158/1535-7163.MCT-13-0084. Epub 2013 Aug 6.

21.

Identification of autophagosome-associated proteins and regulators by quantitative proteomic analysis and genetic screens.

Dengjel J, Høyer-Hansen M, Nielsen MO, Eisenberg T, Harder LM, Schandorff S, Farkas T, Kirkegaard T, Becker AC, Schroeder S, Vanselow K, Lundberg E, Nielsen MM, Kristensen AR, Akimov V, Bunkenborg J, Madeo F, Jäättelä M, Andersen JS.

Mol Cell Proteomics. 2012 Mar;11(3):M111.014035. doi: 10.1074/mcp.M111.014035. Epub 2012 Feb 6.

22.

Induction of humoral and cellular immune responses against the HIV-1 envelope protein using γ-retroviral virus-like particles.

Kirkegaard T, Wheatley A, Melchjorsen J, Bahrami S, Pedersen FS, Center RJ, Purcell DF, Ostergaard L, Duch M, Tolstrup M.

Virol J. 2011 Aug 1;8:381. doi: 10.1186/1743-422X-8-381.

23.

Activation of phospholipase A2 by Hsp70 in vitro.

Mahalka AK, Code C, Jahromi BR, Kirkegaard T, Jäättelä M, Kinnunen PK.

Biochim Biophys Acta. 2011 Oct;1808(10):2569-72. doi: 10.1016/j.bbamem.2011.06.002. Epub 2011 Jun 13. Erratum in: Biochim Biophys Acta. 2014 Jul;1838(7):1921. Rezaijahromi, Behnam [corrected to Jahromi, Behnam Rezai].

24.

HSP70 and lysosomal storage disorders: novel therapeutic opportunities.

Petersen NH, Kirkegaard T.

Biochem Soc Trans. 2010 Dec;38(6):1479-83. doi: 10.1042/BST0381479.

PMID:
21118111
25.

Connecting Hsp70, sphingolipid metabolism and lysosomal stability.

Petersen NH, Kirkegaard T, Olsen OD, Jäättelä M.

Cell Cycle. 2010 Jun 15;9(12):2305-9. Epub 2010 Jun 15.

PMID:
20519957
26.

Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology.

Kirkegaard T, Roth AG, Petersen NH, Mahalka AK, Olsen OD, Moilanen I, Zylicz A, Knudsen J, Sandhoff K, Arenz C, Kinnunen PK, Nylandsted J, Jäättelä M.

Nature. 2010 Jan 28;463(7280):549-53. doi: 10.1038/nature08710.

PMID:
20111001
27.

Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH.

Kirkegaard T, Witton CJ, Edwards J, Nielsen KV, Jensen LB, Campbell FM, Cooke TG, Bartlett JM.

Histopathology. 2010 Jan;56(2):203-11. doi: 10.1111/j.1365-2559.2009.03467.x.

PMID:
20102399
28.

BAMLET activates a lysosomal cell death program in cancer cells.

Rammer P, Groth-Pedersen L, Kirkegaard T, Daugaard M, Rytter A, Szyniarowski P, Høyer-Hansen M, Povlsen LK, Nylandsted J, Larsen JE, Jäättelä M.

Mol Cancer Ther. 2010 Jan;9(1):24-32. doi: 10.1158/1535-7163.MCT-09-0559. Epub 2010 Jan 6.

29.

Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance.

Sonne-Hansen K, Norrie IC, Emdal KB, Benjaminsen RV, Frogne T, Christiansen IJ, Kirkegaard T, Lykkesfeldt AE.

Breast Cancer Res Treat. 2010 Jun;121(3):601-13. doi: 10.1007/s10549-009-0506-y. Epub 2009 Aug 21.

PMID:
19697122
30.

Depletion of kinesin 5B affects lysosomal distribution and stability and induces peri-nuclear accumulation of autophagosomes in cancer cells.

Cardoso CM, Groth-Pedersen L, Høyer-Hansen M, Kirkegaard T, Corcelle E, Andersen JS, Jäättelä M, Nylandsted J.

PLoS One. 2009;4(2):e4424. doi: 10.1371/journal.pone.0004424. Epub 2009 Feb 10.

31.

Frequent amplifications and deletions of G1/S-phase transition genes, CCND1 and MYC in early breast cancers: a potential role in G1/S escape.

Jensen LB, Bartlett JM, Witton CJ, Kirkegaard T, Brown S, Müller S, Campbell F, Cooke TG, Nielsen KV.

Cancer Biomark. 2009;5(1):41-9. doi: 10.3233/CBM-2009-0570.

PMID:
19242061
32.

Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients.

McGlynn LM, Kirkegaard T, Edwards J, Tovey S, Cameron D, Twelves C, Bartlett JM, Cooke TG.

Clin Cancer Res. 2009 Feb 15;15(4):1487-95. doi: 10.1158/1078-0432.CCR-07-4967.

33.

Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium.

Pedersen G, Saermark T, Kirkegaard T, Brynskov J.

Clin Exp Immunol. 2009 Feb;155(2):257-65. doi: 10.1111/j.1365-2249.2008.03836.x.

34.

Lysosomal involvement in cell death and cancer.

Kirkegaard T, Jäättelä M.

Biochim Biophys Acta. 2009 Apr;1793(4):746-54. doi: 10.1016/j.bbamcr.2008.09.008. Epub 2008 Oct 2. Review.

35.

Development of new predictive markers for endocrine therapy and resistance in breast cancer.

Henriksen KL, Sonne-Hansen K, Kirkegaard T, Frogne T, Lykkesfeldt AE.

Acta Oncol. 2008;47(4):795-801. doi: 10.1080/02841860802026993. Review.

PMID:
18465351
36.

Expression of tumor necrosis factor alpha converting enzyme in endocrine cancers.

Kirkegaard T, Naresh A, Sabine VS, Tovey SM, Edwards J, Dunne B, Cooke TG, Jones FE, Bartlett JM.

Am J Clin Pathol. 2008 May;129(5):735-43. doi: 10.1309/N6YB6YDVF58YCNHN.

PMID:
18426733
37.

Genetic alterations of CCND1 and EMSY in breast cancers.

Kirkegaard T, Nielsen KV, Jensen LB, Campbell FM, Müller S, Tovey SM, Brown S, Cooke TG, Bartlett JM.

Histopathology. 2008 May;52(6):698-705. doi: 10.1111/j.1365-2559.2008.03007.x. Epub 2008 Apr 2.

PMID:
18393977
38.

Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.

Kirkegaard T, McGlynn LM, Campbell FM, Müller S, Tovey SM, Dunne B, Nielsen KV, Cooke TG, Bartlett JM.

Clin Cancer Res. 2007 Mar 1;13(5):1405-11.

39.

Bad expression predicts outcome in patients treated with tamoxifen.

Cannings E, Kirkegaard T, Tovey SM, Dunne B, Cooke TG, Bartlett JM.

Breast Cancer Res Treat. 2007 Apr;102(2):173-9. Epub 2006 Sep 27.

PMID:
17004114
40.

Observer variation in immunohistochemical analysis of protein expression, time for a change?

Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, Tam L, Munro AF, Dunne B, Bartlett JM.

Histopathology. 2006 Jun;48(7):787-94.

PMID:
16722926
41.

AKT activation predicts outcome in breast cancer patients treated with tamoxifen.

Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, Bartlett JM.

J Pathol. 2005 Oct;207(2):139-46.

PMID:
16088978
42.

A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells.

Andersen TL, del Carmen Ovejero M, Kirkegaard T, Lenhard T, Foged NT, Delaissé JM.

Bone. 2004 Nov;35(5):1107-19.

PMID:
15542036
43.
44.

Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new lesson on the involvement of MMPs in bone resorption.

Hou P, Troen T, Ovejero MC, Kirkegaard T, Andersen TL, Byrjalsen I, Ferreras M, Sato T, Shapiro SD, Foged NT, Delaissé JM.

Bone. 2004 Jan;34(1):37-47.

PMID:
14751561
45.

Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells.

Kirkegaard T, Pedersen G, Saermark T, Brynskov J.

Clin Exp Immunol. 2004 Jan;135(1):146-53.

46.

An assessment of ADAMs in bone cells: absence of TACE activity prevents osteoclast recruitment and the formation of the marrow cavity in developing long bones.

Boissy P, Lenhard TR, Kirkegaard T, Peschon JJ, Black RA, Delaissé JM, del Carmen Ovejero M.

FEBS Lett. 2003 Oct 23;553(3):257-61.

47.

Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression.

Karsdal MA, Hjorth P, Henriksen K, Kirkegaard T, Nielsen KL, Lou H, Delaissé JM, Foged NT.

J Biol Chem. 2003 Nov 7;278(45):44975-87. Epub 2003 Aug 20.

48.

Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease.

Brynskov J, Foegh P, Pedersen G, Ellervik C, Kirkegaard T, Bingham A, Saermark T.

Gut. 2002 Jul;51(1):37-43.

49.

The role of beta-strand 5A of plasminogen activator inhibitor-1 in regulation of its latency transition and inhibitory activity by vitronectin.

Jensen S, Kirkegaard T, Pedersen KE, Busse M, Preissner KT, Rodenburg KW, Andreasen PA.

Biochim Biophys Acta. 2002 Jun 3;1597(2):301-10.

PMID:
12044908
50.

Vitronectin and substitution of a beta-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against alpha-helix F.

Schousboe SL, Egelund R, Kirkegaard T, Preissner KT, Rodenburg KW, Andreasen PA.

Thromb Haemost. 2000 May;83(5):742-51.

PMID:
10823273

Supplemental Content

Loading ...
Support Center